Build status - In Progress

2D AND 4D CONTRAST-ENHANCED ULTRASOUND EVALUATION OF HEPATOCELLULAR CARCINOMA CHEMOEMBOLIZATION

2D AND 4D CONTRAST-ENHANCED ULTRASOUND EVALUATION OF HEPATOCELLULAR CARCINOMA CHEMOEMBOLIZATION
Recruiting
99 years or below
All
70 participants needed
1 Location

Brief description of study

This is an open-label, non-randomized trial that will be conducted at three clinical sites. The subject population will be patients undergoing transarterial chemoembolization (TACE) for the treatment of hepatocellular carcinoma (HCC) at Thomas Jefferson University, The University of California, San Diego, and University of Pennsylvania. Patients will receive a contrast-enhanced ultrasound (CEUS) exam the morning prior to embolization, approximately one week post-embolization, and at their one month MRI follow up. The goal is to determine if CEUS can detect residual viable tumor after TACE with greater reliability than MRI.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: ['Hepatocellular Carcinoma', 'Chemoembolization, Therapeutic']
  • Age: 99 years or below
  • Gender: All
Updated on 04 Aug 2024. Study ID: 828782

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center